Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID...
April 21 2017 - 8:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced seven data presentations at the 27th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID), taking
place April 22-25 in Vienna, Austria. Presentations will include
information about the company’s lead drug candidate, eravacycline,
as well as data from its TP-6076 program.
“The data we are presenting at ECCMID this year continue to
demonstrate the potent activity of eravacycline against a wide
range of bacteria, including multidrug-resistant pathogens that
cause some of the most serious and life-threatening infections,”
said Guy Macdonald, President and Chief Executive Officer of
Tetraphase Pharmaceuticals. “Eravacycline data show potent activity
against many of the organisms identified by the World Health
Organization and the U.S. Centers for Disease Control to pose
urgent or serious threats to human health, specifically
Gram-negative bacteria Acinetobacter baumannii and
Enterobacteriaceae, including carbapenem-resistant or extended
beta-lactamase producing phenotypes, as well as Gram-positive
bacteria Staphylococcus aureus and enterococci, including
methicillin- or vancomycin-resistant phenotypes.”
Mr. Macdonald continued, “We are also very excited about the
emerging profile of our earlier stage compound, TP-6076. Data
presentations at ECCMID highlight its potency against
multidrug-resistant Acinetobacter baumannii and
carbapenem-resistant Enterobacteriaceae, demonstrated in clinical
isolates that were pan-resistant to multiple antibiotic
classes.”
The details for the data presentations at ECCMID are as
follows:
Eravacycline presentations:
Poster Title: In vitro activity of
eravacycline and comparators against Staphylococcus aureus and
enterococci, including methicillin-resistant and
vancomycin-resistant subgroups, collected from European hospitals
in 2015Date and time: Monday, April 24 from 12:30
– 1:30 p.m. CESTLocation: Poster
AreaPoster number: #P1358Session
info: Drugs against Gram-positives – more data; Paper
poster session
Poster Title: In vitro activity of eravacycline
and comparators against Acinetobacter baumannii, Stenotrophomonas
maltophilia and Enterobacteriaceae, including carbapenem-resistant
and ESBL phenotype subgroups, collected from European hospitals in
2015Date and time: Monday, April 24 from 12:30 –
1:30 p.m. CESTLocation: Poster AreaPoster
number: #P1260Session info: New data on
new tetracyclines; Paper poster session
Poster title: Comparative in vitro
activity of eravacycline, a novel fluorocycline, against
mcr-1-positive Escherichia coli & Klebsiella
pneumoniaeDate and time: Monday, April 24 from
12:30 – 1:30 p.m. CESTLocation: Poster
AreaPoster number: #P1258Session
info: New data on new tetracyclines; Paper poster
session
Poster title: Eravacycline, a novel
fluorocycline, has antibacterial activity against
carbapenem-resistant Enterobacteriaceae (CRE) & Acinetobacter
spp. (CRA)Date and time: Monday, April 24 from
12:30 – 1:30 p.m. CESTLocation: Poster
AreaPoster number: #P1259Session
info: New data on new tetracyclines; Paper poster
session
Poster title: Antibacterial activity of
eravacycline, a novel fluorocycline, compared to established
antimicrobials, against contemporary clinical isolates from Tanta,
Egypt.Date and time: Monday, April 24 from
12:30-1:30 p.m. CESTLocation: Poster
AreaPoster number: #P1261Session
info: New data on new tetracyclines; Paper poster
session
TP-6076 presentations:
Poster title: In-vitro activity of the
novel fluorocycline TP-6076 against carbapenem non-susceptible
Acinetobacter baumanniiDate and time: Monday,
April 24 from 12:30-1:30 p.m. CESTLocation: Poster
AreaPoster number: #P1364Session
info: New discoveries against Gram-negatives; Paper poster
session
Poster title: TP-6076 is active against
Carbapenem- and Polymyxin-resistant Enterobacteriaceae and
Acinetobacter baumannii isolates in the FDA-CDC Antimicrobial
Resistance Isolate Bank Panels.Date and time:
Monday, April 24 from 12:30-1:30 p.m.
CESTLocation: Poster AreaPoster
number: #P1365Session info: New
discoveries against Gram-negatives; Paper poster session
Full abstracts can be found on the ECCMID website at
http://www.eccmid.org/.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical trials, and TP-271 and TP-6076, which are in
phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Forward-Looking StatementsAny statements in
this press release about our future expectations, plans and
prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, and other statements
containing the words "anticipates," "believes," "expects," "plans,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: whether results obtained in previous
clinical trials will be indicative of results obtained in future
clinical trials; whether eravacycline or any other clinical
candidate will advance through the clinical trial process on a
timely basis or at all; whether the results of the Company's
development efforts will warrant regulatory submission and whether
any such submissions will receive approval from the United States
Food and Drug Administration or equivalent foreign regulatory
agencies; whether, if any clinical candidate obtains approval, it
will be successfully distributed and marketed; and other factors
discussed in the "Risk Factors" section of our quarterly report on
Form 10-K, filed with the Securities and Exchange Commission on
March 13, 2017. In addition, the forward-looking statements
included in this press release represent our views as of April 21,
2017. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so.
Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
tdahlman@tphase.com
Argot Partners
Maeve Conneighton
206-899-4940
maeve@argotpartners.com
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024